Assembly Biosciences Inc (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $45.04, for a total value of $45,040.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Assembly Biosciences Inc (NASDAQ:ASMB) traded down $0.53 during trading on Thursday, hitting $45.75. The company had a trading volume of 96,600 shares, compared to its average volume of 113,750. The stock has a market cap of $788.20, a P/E ratio of -15.40 and a beta of 0.90. Assembly Biosciences Inc has a 52 week low of $11.89 and a 52 week high of $52.37.
A number of research analysts have weighed in on ASMB shares. Zacks Investment Research upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Wednesday, November 15th. Jefferies Group started coverage on Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. BidaskClub downgraded Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. ValuEngine downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Finally, Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $40.67.
ILLEGAL ACTIVITY NOTICE: This article was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3125734/assembly-biosciences-inc-asmb-director-william-r-ringo-sells-1000-shares.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.